/
Innoviva, Inc. ( Innoviva , the Company , the Registrant or we and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ( IST ), and a portfolio of strategic healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group…
39.81% operating margin is above average. ROIC at 8.36%. Note that capital returns lag the margin, the business may be capital-intensive despite high margins.
Revenue up 14.7% YoY with margins expanding 29.4pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$421M
▲ +14.7% YoY
Net Income (TTM)
$504M
▲ +1059.2% YoY
Op. Margin
38.14%
▲ +29.4pp YoY
ROIC
9.24%
▲ +6.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$184M
▲ +3.9% YoY
Op. Cash Flow (TTM)
$184M
▲ +4.4% YoY
Net Debt
-$334M
Net Cash Position
Cash & Equiv.
$603M
5Y CAGR: +4.1%
5Y CAGR: -9.0%
Continue Research